Noboru Kawata

Noboru Kawata

Auto-generated profile, based on publicly available information

Noboru Kawata

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2015 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
MYMasao Yoshida
Masao Yoshida
KTKOHEI TAKIZAWA
KOHEI TAKIZAWA
HOHiroyuki Ono
Hiroyuki Ono
KIKimihiro Igarashi
Kimihiro Igarashi
SSShinya Sugimoto
Shinya Sugimoto
HMHiroyuki Matsubayashi
Hiroyuki Matsubayashi

22 January 2018 in Gastric Cancer
Verified
Journal Article
Closed access
PDF file
NKNoboru Kawata
Noboru Kawata
HOHiroyuki Ono
Hiroyuki Ono
KTKohei Takizawa
Kohei Takizawa
NKNaomi Kakushima
Naomi Kakushima
MTMasaki Tanaka
Masaki Tanaka
HMHiroyuki Matsubayashi
Hiroyuki Matsubayashi

Verified
Journal Article
Open access
PDF file
HMHiroyuki Matsubayashi
Hiroyuki Matsubayashi
HIHirotoshi Ishiwatari
Hirotoshi Ishiwatari
KIKenichiro Imai
Kenichiro Imai
YKYoshihiro Kishida
Yoshihiro Kishida
SISayo Ito
Sayo Ito
HOHiroyuki Ono
Hiroyuki Ono
Autoimmune pancreatitis (AIP), a unique subtype of pancreatitis, is often accompanied by systemic inflammatory disorders. AIP is classified into two distinct subtypes on the basis of the histological subtype: immunoglobulin G4 (IgG4)-related lymphoplasmacytic sclerosing pancreatitis (type 1) and idiopathic duct-centric pancreatitis (type 2). Type 1 AIP is often accompanied by systemic lesions, biliary strictures, hepatic inflammatory pseudotumors, interstitial pneumonia and nephritis, dacryoadenitis, and sialadenitis. Type 2 AIP is associated with inflammatory bowel diseases in approximately 30% of cases. Standard therapy for AIP is oral corticosteroid administration. Steroid treatment is generally indicated for symptomatic cases and is exceptionally applied for cases with diagnostic difficulty (diagnostic steroid trial) after a negative workup for malignancy. More than 90% of patients respond to steroid treatment within 1 month, and most within 2 weeks. The steroid response can be confirmed on clinical images (computed tomography, ultrasonography, endoscopic ultrasonography, magnetic resonance imaging, and 18F-fluorodeoxyglucose-positron emission tomography). Hence, the steroid response is included as an optional diagnostic item of AIP. Steroid treatment results in normalization of serological markers, including IgG4. Short- and long-term corticosteroid treatment may induce adverse events, including chronic glycometabolism, obesity, an immunocompromised status against infection, cataracts, glaucoma, osteoporosis, and myopathy. AIP is common in old age and is often associated with diabetes mellitus (33–78%). Thus, there is an argument for corticosteroid therapy in diabetes patients with no symptoms. With low-dose steroid treatment or treatment withdrawal, there is a high incidence of AIP recurrence (24–52%). Therefore, there is a need for long-term steroid maintenance therapy and/or steroid-sparing agents (immunomodulators and rituximab). Corticosteroids play a critical role in the diagnosis and treatment of AIP.

1 November 2017 in Pancreatology
Verified
Journal Article
Closed access
YYYukio Yoshida
Yukio Yoshida
AFAkira Fukutomi
Akira Fukutomi
MTMasaki Tanaka
Masaki Tanaka
TSTeiichi Sugiura
Teiichi Sugiura
NKNoboru Kawata
Noboru Kawata
HYHirofumi Yasui
Hirofumi Yasui

14 December 2018 in Digestion
Verified
Journal Article
Closed access
PDF file
KTKOHEI TAKIZAWA
KOHEI TAKIZAWA
WHWaku Hatta
Waku Hatta
TGTakuji Gotoda
Takuji Gotoda
NKNoboru Kawata
Noboru Kawata
MNMasahiro Nakagawa
Masahiro Nakagawa
TSTooru Shimosegawa
Tooru Shimosegawa
Background/Aims: The outcomes of salvage surgery for recurrence after non-curative endoscopic submucosal dissection (ESD) without additional radical surgery for early gastric cancer (EGC) remain unclear. We determined the recurrence patterns and outcomes of salvage surgery in such cases using data from a multicenter, retrospective study. Methods: Of 15,785 patients who underwent ESD for EGC at 19 participating institutions between January 2000 and August 2011, 1,969 failed to meet the current curative criteria after ESD. Of these, 905 patients received no additional treatment. We evaluated the pattern of recurrence, clinical course after salvage surgery, and long-term survival rate for these patients. Results: Over a median 64-month follow-up period, recurrence was detected in 27 patients. Two patients with missing data were excluded. Three, seven, and 15 (60%) patients showed intragastric relapse, regional lymph node metastasis, and distant metastasis, respectively. The first line of treatment for recurrence in 1, 7, 6, and 11 patients was endoscopic treatment, salvage surgery, chemotherapy, and best supportive care, respectively. One patient survived without recurrence for 31 months after salvage surgery, one died of acute myocardial infarction 1 month after salvage surgery, and 5 showed recurrence at 0, 2, 3, 5, and 30 months after salvage surgery and eventually succumbed to the disease. The median survival times for all patients with recurrence and the 7 patients who underwent salvage surgery were 5 months after recurrence and 7 months after salvage surgery, respectively. Conclusion: The survival rate after salvage surgery for recurrence after non-curative ESD without additional radical surgery for EGC is quite low, with distant metastasis being the most common recurrence pattern in these cases.

11 August 2021 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
YKYoshihiro Kishida
Yoshihiro Kishida
KTKOHEI TAKIZAWA
KOHEI TAKIZAWA
NKNaomi Kakushima
Naomi Kakushima
NKNoboru Kawata
Noboru Kawata
MYMasao Yoshida
Masao Yoshida
HOHiroyuki Ono
Hiroyuki Ono